다형교아종치료 시장 규모, 점유율, 성장 분석 : 치료 유형별, 최종사용자별, 지역별 - 산업별 예측(2024-2031년)

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.46 billion in 2022 and is poised to grow from USD 2.70 billion in 2023 to USD 5.66 billion by 2031, growing at a CAGR of 9.7% during the forecast period (2024-2031).

The glioblastoma multiforme treatment market is poised for substantial growth, driven by a surge in glioblastoma cases and a heightened focus on research and development. Major pharmaceutical companies are bolstering their product pipelines, responding to the alarming statistics from the Global Cancer Observatory, which noted over 251,000 deaths and 308,000 diagnoses of brain cancers in 2020. Added evidence from the WHO in 2021 highlighted more than 245,000 occurrences of such tumors, amplifying the need for effective treatment options. However, the market faces hurdles, including high treatment costs and the challenge of developing effective therapies for this aggressive cancer. Nevertheless, opportunities abound in immunotherapy, targeted treatments, and innovative combinations, fueled by advancements in personalized medicine and promising clinical trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glioblastoma Multiforme Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors), immunotherapy (checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market is primarily driven by several key factors. The increasing prevalence of glioblastoma, a particularly aggressive form of brain cancer, continues to spur demand for effective treatment options. Advancements in medical technology and innovative therapeutic approaches, such as targeted therapies and immunotherapy, are enhancing treatment efficacy and patient outcomes. Additionally, rising investments in research and development, along with the growing focus on personalized medicine, are fostering the introduction of new drugs and therapies into the market. Moreover, heightened awareness of glioblastoma and improved access to healthcare services are contributing to market expansion globally.

Restraints in the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market faces several constraints that could hinder its growth. Key challenges include the high costs associated with treatment options, which may limit access for many patients. Additionally, the complex nature of glioblastoma, characterized by its aggressive behavior and resistance to conventional therapies, presents a significant barrier to effective treatment. Furthermore, a lack of robust clinical data and ongoing research may delay the introduction of new and innovative therapies. Regulatory hurdles and the need for extensive clinical trials can also impede market expansion, while the limited number of healthcare professionals specializing in this area adds to the market's challenges.

Market Trends of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme (GBM) Treatment market is witnessing a significant trend towards increased adoption of personalized medicine, revolutionizing standard treatment paradigms. This shift leverages advancements in genetic profiling and biomarker testing, enabling healthcare providers to tailor therapies to the unique characteristics of each patient's tumor. Such precision approaches not only enhance treatment efficacy but also minimize the risk of adverse effects, reflecting a broader movement towards individualized healthcare solutions. As stakeholders invest in research and technology to develop targeted therapies, the market is poised for growth, driven by rising awareness and the potential for improved patient outcomes in GBM management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Glioblastoma Multiforme Treatment Market Size by Treatment Type & CAGR (2024-2031)

• Market Overview
• Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • Others
• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy
• Targeted Therapy
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
• Immunotherapy
  • Checkpoint Inhibitors
  • Vaccine Therapy
• Tumor Treating Fields (TTF) Therapy
• Surgery
  • Craniotomy
  • Biopsy

Global Glioblastoma Multiforme Treatment Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes

Global Glioblastoma Multiforme Treatment Market Size & CAGR (2024-2031)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation